Objective-The efficiency of cell therapy is limited by poor cell survival and engraftment. Here, we studied the effect of the growth hormone-releasing hormone agonist, JI-34, on mesenchymal stem cell (MSC) survival and angiogenic therapy in a mouse model of critical limb ischemia. Approach and Results-Mouse bone marrow-derived MSCs were incubated with or without 10 -8 mol/L JI-34 for 24 hours.
C ell-based therapies show promise to promote regeneration and angiogenesis and reverse or rescue tissues injured by ischemia or infarct. In this context, various kinds of progenitor cells have been tested clinically, including cardiac progenitor cells, 1 endothelial progenitor cells, 2 induced pluripotent stem cells, 3 embryonic stem cells, 4 bone marrow mononuclear cells, 5 and mesenchymal stem cells (MSCs), 6 with mixed outcomes. MSCs have the advantages of immune privilege, stemness, and ease of handling relative to other cell types and have become prominent vehicles for a wide range of indications. 7 The mechanism of MSC action is thought to be primarily paracrine. 8 When exogenously administered, MSCs can facilitate the formation of new capillaries and mediumsized arteries. However, therapeutic angiogenesis by MSCs is limited by poor survival especially in the hostile microenvironment of ischemic tissue. Many different approaches have been attempted to improve the efficacy of MSC therapy, including pretreating with various chemicals or polypeptides, 9, 10 preconditioning with physiological stimuli such as hypoxia, 11 or combination with other cells including endothelial progenitor cells 12 and endothelial cells. 13 Optimal conditions have not been achieved.
Growth hormone-releasing hormone (GHRH) is a neuropeptide produced by the hypothalamus. It is carried to the anterior pituitary through the portal vessels and stimulates the release of growth hormone after binding to the GHRH receptor (GHRH-R) on cell membranes. 14 Previous studies have shown that GHRH and its receptor are also expressed on cells in normal human tissues, for example, liver, kidney, lung, and prostate, as well as many tumors. 15, 16 GHRH and its agonists have been used to treat disorders of the endocrine system, as well as to promote cell proliferation and functional recovery in extrapituitary tissues. 17, 18 Compared with the native GHRH, synthetic agonists are much more potent and longer acting because of increased stability. 14 One such GHRH agonist, JI-38, has been used to accelerate wound healing primarily by acting on wound-associated fibroblasts. 19 The systemic administration of GHRH agonists has been shown to stimulate the recovery of cardiac function after infarction or ischemia/reperfusion injury by reducing apoptosis of cardiomyocytes, enhancing the recruitment of endogenous cardiac stem cells, stimulating angiogenesis in heart, and ameliorating cardiac remodeling. 17, 20, 21 Because GHRH-R is expressed in MSCs, 22 we hypothesized that pretreatment of MSCs with such agonists may improve therapeutic properties of MSCs. Here, we demonstrate that JI-34, a potent GHRH agonist, indeed improves MSC proliferation and homing and, thus, augments therapy by promoting angiogenesis in ischemic skeletal muscle of mouse hindlimb.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

GHRH-R Is Expressed on Mouse Bone Marrow-Derived MSCs
GHRH-R expression on mouse bone marrow-derived MSCs was detected by Western blot ( Figure 1A ), flow cytometry ( Figure 1B) , and immunofluorescence staining ( Figure IA in the online-only Data Supplement). The results from both Western blot and immunofluorescence staining demonstrate that MSCs express levels of GHRH-R that are similar to the brain, whereas skeletal muscle was negative for GHRH-R expression. Flow cytometry showed that the mean fluorescence intensity of GHRH-R on MSCs was 224.3±34.6 ( Figure 1B) , which was not significantly changed after cells were treated with GHRH agonist, JI-34 ( Figure IB and IC in the online-only Data Supplement). These results were further confirmed by Western blot assay ( Figure ID in the onlineonly Data Supplement). These data confirm that GHRH-R is expressed on MSCs.
GHRH Agonist Preconditioning Enhances Proliferation and Survival of MSCs
To investigate the effects of JI-34 on cell proliferation and viability, we treated MSCs with increasing concentrations of JI-34 for 48 hours and quantified resulting cell numbers. Figure 1C shows that the proliferation of MSCs was optimally enhanced (114±8%) by JI-34 at a concentration of 1×10 −8 mol/L. The viability of MSCs after culture under hypoxia (0.5% O 2 ) with serum deprivation for 48 hours was significantly increased by JI-34 pretreatment when compared with the untreated MSCs ( Figure 1D ). Augmentation of MSC proliferation and viability was optimal at JI-34 concentration of 1×10 −8 mol/L; therefore, this concentration was used for further studies.
Apoptosis of MSCs after culture under the hypoxia with serum deprivation condition for 48 hours was determined by flow cytometric analysis of Annexin V + cells ( Figure 1E ). The rate of apoptosis was reduced from 50.3%±9.1 for untreated cells to 32.9%±7.5 when the cells were pretreated with JI-34, whereas cytoprotection by JI-34 treatment was blocked by cotreatment with GHRH antagonist, MIA-602 ( Figure 1F ).
JI-34 Increased Phosphorylation and Translocation of STAT3 in MSCs
Signal transducer and activator of transcription 3 (STAT3) plays an important role in the promotion of angiogenesis, cell survival, and proliferation. 23 To evaluate potential downstream GHRH-R signaling, the activation of STAT3 was examined. Treatment of MSCs with JI-34 resulted in an increase of STAT3 phosphorylation (Figure 2A ). The ratio of phosphorylated STAT3 compared with total STAT3 (P-STAT3/T-STAT3) was significantly increased by 5 minutes of treatment with JI-34 and reached a plateau at 30 minutes ( Figure 2B ). Immunofluorescence staining of STAT3 ( Figure 2C ) revealed that the majority of STAT3 was in the cytoplasm in control cultures but translocated to the nucleus after treatment with JI-34. Translocation was blocked by GHRH antagonist, MIA-602 ( Figure 2D ). To further investigate the possible targets of JI-34, the expression of c-myc, a downstream target of STAT3, was analyzed. The expression of c-myc transcripts in MSCs was increased ≈200-fold by JI-34 treatment, and this was blocked by GHRH-R antagonist, MIA-602 ( Figure 
JI-34 Enhances Mobility and Proangiogenic Activity of MSCs In Vitro
In vitro transwell migration assays ( Figure 3A ) showed that the mobility of MSCs was significantly increased after the cells were treated with JI-34, and this was blocked by GHRH antagonist, MIA-602 ( Figure 3B ). To further characterize the possible paracrine effect of MSCs treated with JI-34, MSC-conditioned medium was used to culture human umbilical vein endothelial cells and endothelial tube formation was measured using a Matrigel assay ( Figure 3C SVs splice variants of angiogenesis-related genes ( Table 1 in the online-only Data Supplement). The mRNA levels of vascular endothelial growth factor-A and stromal-derived factor-1 were increased by 9-fold and 2.5-fold, respectively, by treatment with JI-34 ( Figure 3F ). This effect was blocked by GHRH antagonist, MIA-602, or WP1066, a STAT3 inhibitor. Meanwhile, we also observed that the protein expression level of hepatocyte growth factor, vascular endothelial growth factor, and stromal-derived factor-1 was increased in MSC pretreated with JI-34, and this effect could be abolished by the addition of MIA-602 ( Figure 3E ). In addition, we studied the effects of another novel GHRH-R agonist, MR-409. Compared with JI-34, MR-409 is superior in stability and activity. 18 
GHRH Agonist Augments Survival of MSCs In Vivo
To investigate homing and engraftment of MSCs in ischemic muscle, transplantations of sex-mismatched and green fluorescent protein (GFP)-labeled cells were performed, and the number of retained donor cells in a recipient was examined by detecting the male-specific Sry and GFP genes on days 3, 7, and 14 after injection of cells into ischemic muscles. Significantly more donor cells were detected in the ischemic muscle of mice injected with MSCs preconditioned with JI-34 compared with untreated MSCs 3 and 7 days after cell transplantation, and a similar, but nonsignificant, trend was observed on day 14 post-transplantation ( Figure 4A ; Figure V in the online-only Data Supplement). This was confirmed by 
Pretreatment With JI-34 Enhances MSC Therapy in Ischemic Hindlimb
Reperfusion of ischemic mouse hind limbs was measured using laser Doppler perfusion imaging at intervals after femoral artery ligation ( Figure 4B ). Mice that received JI-34conditioned MSCs recovered perfusion significantly faster than those that received untreated MSC or control groups ( Figure 4C ). Toe necrosis in ischemic limbs was also reduced in the JI-34-treated MSC group compared with that in the untreated MSC or control groups ( Figure 4D and 4E ).
Pretreatment of MSCs With JI-34 Augments Angiogenesis and Muscle Regeneration In Vivo
Muscle regeneration was analyzed by measuring central-localized nuclei in muscle cells of recovered tissues ( Figure 5A ). Administration of MSCs treated with agonist significantly increased the number of regenerating myofibers in ischemic gastrocnemius muscles 21 days after surgery ( Figure 5B ).
To investigate whether the recovery of blood perfusion was associated with angiogenic activity, capillary density of ischemic muscles was analyzed by CD31 immunostaining ( Figure 5C ). Capillary densities were significantly higher in mice that received preconditioned MSCs compared with those that received phosphate-buffered saline (PBS) or untreated MSCs on day 21 after injection ( Figure 5D ). Arteriole density in the ischemic muscles was also determined by immunostaining of smooth muscle α-actin ( Figure 5C ). Transplantation of MSCs preconditioned with JI-34 also resulted in the highest arteriole density of ischemic muscle ( Figure 5E ). However, no direct differentiation of MSCs into endothelial cells was observed ( Figure 5F ).
Enhanced Angiogenesis Is Associated With Increased Proliferation of Endothelial Cells
To further explore the mechanism of augmented angiogenesis by MSCs, proliferation of endothelial cells was analyzed by immunostaining for Ki67 and CD31 in the ischemic muscles on day 7 after cell transplantation ( Figure 6A) . A robustly increased percentage of Ki67-positive cells ( Figure 6B ) and greater percentage of Ki67/CD31 double-positive cells ( Figure 6C ) was observed in mice that received JI-34-treated MSCs compared with those that received PBS or untreated MSCs. Furthermore, we performed real-time polymerase chain reaction to analyze the proangiogenic cytokines content in ischemic muscle. Results showed increased proangiogenic cytokines expression in MSC-JI group compared with other 
Transplantation of MSCs Preconditioned With JI-34 Enhances Recruitment of CD34 + Cells
To determine whether treatment with JI-34 enhanced MSCmediated recruitment of endogenous progenitor cells, CD34positive cells in ischemic muscles from each group at day 3 postsurgery were quantified ( Figure 6D ). As expected, JI-34treated MSCs resulted in significantly more CD34 + cells compared with all other groups ( Figure 6E ).
Reduction of Cell Apoptosis In Vivo by MSCs Preconditioned With JI-34
To determine the mechanism of cell protection by preconditioned MSCs, antiapoptotic proteins were analyzed by Western blot (Figure 7A ). Significantly more B-cell lymphoma-2 protein was detected in the ischemic muscles transplanted with MSCs treated with JI-34 compared with those transplanted with untreated MSCs or PBS ( Figure 7B ).These data implicate the activation of antiapoptotic and inhibition of proapoptotic pathways as mechanisms of cytoprotection by JI-34 in vivo.
Discussion
In this study, we demonstrated that GHRH agonist, JI-34, significantly enhanced the viability and mobility of MSCs.
After treatment with the agonist, the production of cytokines from MSCs was augmented, and the therapeutic effects in a mouse model of critical limb ischemia were significantly augmented compared with untreated MSCs. JI-34 agonist bound to a GHRH-R on MSCs and activated downstream STAT3/cmyc signaling and antiapoptotic pathways. These effects of agonist JI-34 were blocked by the GHRH antagonist, MIA-602, confirming an essential role for GHRH-R binding. MSCs pretreated with JI-34 displayed improved survival in ischemic muscles relative to untreated MSCs. Administration of MSCs treated with JI-34 into ischemic limbs significantly enhanced local angiogenesis, resulting in better reperfusion and limb salvage. More capillaries and mature vessels were observed in the ischemic muscles that received JI-34-treated MSCs. The effect of MSCs in vivo was associated with enhanced EC proliferation and recruitment of CD34 + progenitor cells. Transdifferentiation of MSCs into vascular cells was rarely observed, indicating a primary paracrine role of MSCs in promoting angiogenesis. Previous work has shown that systemic administration of GHRH agonists stimulates proliferation of cells in peripheral tissues. Dioufa et al 19 reported that the GHRH agonist, JI-38, improved wound healing by activating wound-associated fibroblasts through GHRH-R binding. It has been shown that rat cardiomyocytes express pituitary-type GHRH-R, and administration of exogenous GHRH was cardioprotective by preventing apoptosis and reducing the cardiac scar size. This was attributed to activation of extracellular regulated protein kinases1/2, phosphoinositide 3-kinase/protein kinase B and adenylate cyclase/cyclic adenosine monophosphate/ protein kinase A signaling pathways. 17 Subcutaneous injection of GHRH agonist, JI-38, into rats with acute myocardial infarction improved angiogenesis and cardiac remodeling. 24 The effects of JI-38 include the augmentation of cardiac precursor cell proliferation without elevating systemic growth hormone levels. 20 In addition, GHRH agonist, MR403, was shown to increase viability and proliferation of islet cells, thereby improving the survival of cultured insulinoma cells, suggesting promise for improved islet transplantation. 25, 26 In this study, we observed that JI-34 preconditioning increased MSC proliferation and survival. However, MSCs preconditioned with high concentration of JI-34 (10 −7 mol/L) did not exhibit obvious protective effect. We speculated that JI-34 at low concentration will promote cell proliferation and survival but causes cytotoxicity at high concentration. All GHRH analogs exhibited higher biological activity and are more stable than crude GHRH. 14 The biological activities of both JI-38 and MR403 are similar or virtually identical. 14, 18 To our knowledge, this study is the first to describe a positive therapeutic benefit of MSCs by pretreatment with a GHRH agonist.
Splice variants (SVs) of GHRH-R have been detected in many extrapituitary tissues, including prostate, 27 pancreatic islet, 26 and heart. 17 It has been demonstrated that functional SVs can replace the functions of GHRH pituitary-type receptor. 28 In this study, we detected the expression of 39 kDa GHRH-R SV1 in mouse MSCs (Figure 1 ). Previous studies provided evidence that SV1 plays a pivotal role in regulating cell proliferation and survival. 29 GHRH agonists seem to exert their actions in extrapituitary tissues through direct binding to SV1 without activation of the canonical downstream pathway of growth hormone/insulin-like growth factor axis. 20 Consistent with previous studies, our in vitro data exhibited similar effects of agonist, JI-34, on enhancement of MSC proliferation and viability, whereas the expression of SV1 was not changed after the JI-34 treatment, indicating that the effects of JI-34 on MSCs were not meditated by upregulation of the SV1 receptor. GHRH can also activate Janus kinase 2/signal transducer and activator of transcription 3 pathway. 30 GHRH binds with its receptor and induces STAT3 phosphorylation at tyrosine. 17, 21 Activation of STAT3 has been shown to play a critical role in regulation of angiogenesis and activation of cell survival pathway. 23, 31 Upon activation mediated by JI-34, STAT3 translocates from cytoplasm into the nucleus to regulate gene expression. Our results illustrate that JI-34 preconditioning corresponds to STAT3 activation and possibly its downstream proangiogenic and cell survival pathway. Our data suggested that STAT3 is an important part of GHRH pathway and participates in preconditioning-mediated cytoprotection actions.
MSCs are multipotent stem cells that have been widely used for cell-mediated therapy for various clinical indications including cardiovascular. 32 Transplantation of MSCs has also been used to reduce foot necrosis and to increase perfusion of lower limbs in patients with limb ischemia. 33 Such therapy is limited by poor retention and engraftment of the donor cells. 34 The hostile microenvironment of ischemia leads to massive apoptosis and impaired function of the transplanted cells. Indeed, it has been reported that only 0.35±0.05% of transplanted cells survive 4 weeks after limb transplantation. 35 To overcome these limitations, cell preconditioning by physical, chemical, pharmacological, or genetic modification before transplantation has emerged to augment cell function and therapy. 36 Our previous study showed that hypoxia preconditioning markedly increased the viability and mobility of MSCs through a leptin-mediated mechanism and enhanced therapeutic efficacy of MSCs in a mouse myocardial infarction model. 11 Moreover, preconditioning with chemotactic factor can enhance survival and improve biological function of transplanted cells. 37, 38 Here for the first time, we found that preconditioning MSCs with GHRH agonist, JI-34, significantly protected MSCs from apoptosis induced by serum deprivation and hypoxia stress in vitro consistent with antiapoptosis as a mechanism of cytoprotection and improved therapy by JI-34. 39 In agreement with this, Jaszberenyi et al 40 recently reported that GHRH antagonists increased the expression of proapoptosis protein B-cell lymphoma-2-associated agonist of cell death in U-87 MG glioblastoma cells as reverse evidence. By transplantation of sex-mismatched and GFP-labeled MSCs and subsequent quantification of Sry gene and GFP gene expression from the injected cells, we found that JI-34 treatment markedly improved MSC survival and retention in ischemic limbs 3 and 7 days after cell transplantation. Taken together, our in vitro and in vivo data verified that treating MSCs with JI-34 augments cell homing and maximized the therapeutic effect of transplantation and enhanced generation of cytoprotective and angiogenic cytokines, including vascular endothelial growth factor and stromal-derived factor-1. In support of this, Gomes et al 22 found that GHRH agonists augmented vascular endothelial growth factor-A production in MSCs. However, it is important to note that in our hands, the improved short-term survival by JI-34 treatment was not sustained over a longer period (14 days). Moreover, we failed to detect any MSCderived endothelial cell or α-smooth muscle cell 21 days after transplantation. Therefore, MSC transdifferentiation may not contribute significantly to therapy in this model. Rather, the effects of MSCs are primarily paracrine, affecting both cell activity and recruitment of progenitor cells. We found an increased proangiogenic cytokines expression in the ischemic limb muscle receiving preconditioned MSCs. The latter is also supported by a significant augmentation of CD34 + cells found in the ischemic muscle that received JI-34-treated MSCs relative to controls.
In conclusion, our data demonstrate that preconditioning of MSCs with GHRH agonist, JI-34, enhances the survival and proliferation of MSCs, increases the secretion of proangiogenic factors, and augments the therapeutic potential of MSCs to promote angiogenesis in ischemia tissue. These results support clinical testing of GHRH agonists as agents to improve MSC therapy for cardiovascular indications including critical limb ischemia.
